A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

Vaccine
J S LambertW Koff

Abstract

Thirty-three HIV-seronegative adults were recruited into a Phase I safety and immunogenicity HIV-1 vaccine trial. The immunogens were as follows: a synthetic, monovalent, octameric HIV-1 MN V3 peptide in aluminum hydroxide (alum) adjuvant administered by intramuscular delivery; and a similar product encapsulated in biodegradable micro-spheres composed of co-polymers of lactic and glycolic acids, administered by the oral route. These were administered in three sequential oral doses, followed by a parenteral boost. No serious adverse experiences were observed. Oral administration of this vaccine, alone or in combination with parenteral boosting, resulted in no significant humoral, cellular, or mucosal immune responses.

References

Mar 1, 1992·AIDS Research and Human Retroviruses·G MyersB Korber
Apr 6, 1991·Lancet·B D Forrest
Jul 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·H K LyerlyK J Weinhold
Jul 22, 1988·Science·W C Koff, D F Hoth
Feb 27, 1986·Journal of Immunological Methods·M W RussellJ Mestecky
Jan 1, 1968·Scandinavian Journal of Clinical and Laboratory Investigation·C E Mogensen
Mar 1, 1993·Microbiological Reviews·J A Levy
Jan 1, 1997·AIDS Research and Human Retroviruses·A D KelleherD A Cooper
Apr 13, 1999·Infectious Disease Clinics of North America·S E Frey
Jan 26, 2000·Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie·M GirardC Chanel

❮ Previous
Next ❯

Citations

Jan 8, 2003·The Journal of Gene Medicine·Matilu Mwau, Andrew J McMichael
Jul 5, 2003·International Journal of Pharmaceutics·A M CarcabosoJ L Pedraz
Oct 22, 2005·Nature Reviews. Immunology·Samir Mitragotri
Jan 22, 2004·Viral Immunology·Aldar S BourinbaiarVichai Jirathitikal
Jul 21, 2011·Journal of Drug Delivery·Aiala SalvadorJosé Luis Pedraz
Aug 18, 2004·The Journal of Clinical Investigation·Jay A BerzofskyIgor M Belyakov
Nov 19, 2010·PLoS Pathogens·Ali AziziJiri Mestecky
Mar 30, 2004·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Nicolas BurdinPhilippe Moingeon
Feb 7, 2002·Pharmacoepidemiology and Drug Safety
Apr 19, 2005·American Journal of Reproductive Immunology : AJRI·Jiri MesteckyMichael W Russell
Aug 4, 2009·Reviews in Medical Virology·Jonatan Ersching, Aguinaldo R Pinto
Nov 26, 2010·Expert Review of Vaccines·Antu K Dey, Indresh K Srivastava
Jul 20, 2005·Expert Review of Vaccines·Aldar S Bourinbaiar, Rivka Abulafia-Lapid
Nov 3, 2010·Journal of Drug Targeting·Barbara C Baudner, Derek T O'Hagan
May 11, 2010·Immunological Investigations·Michael W Russell, Jiri Mestecky
Mar 10, 2004·Expert Opinion on Biological Therapy·Maja A SommerfeltBirger Sørensen
Dec 5, 2013·Human Vaccines & Immunotherapeutics·Fazren AzmiIstvan Toth
May 22, 2003·Dermatologic Clinics·Mathijs H BrentjensStephen K Tyring
Aug 28, 2019·Current Immunology Reviews·Pamela A Kozlowski, Anna Aldovini
Dec 9, 2004·AIDS Research and Human Retroviruses·Jiri MesteckyPaul A Goepfert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.